ArticleClinical cancer research : an official journal of the American Association for Cancer Research2010
A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- Nomograms to predict survival of stage IV tongue squamous cell carcinoma after surgery.Medicine · 2019Article
- Performance of prostate cancer recurrence nomograms by obesity status: a retrospective analysis of a radical prostatectomy cohort.BMC cancer · 2018Article
- Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.European urology · 2018Article
- Robust genomic copy number predictor of pan cancer metastasis.Genes & cancer · 2018Article
- Nomogram based on systemic inflammatory response markers predicting the survival of patients with resectable gastric cancer after D2 gastrectomy.Oncotarget · 2016Article
- Development and external validation of a prognostic nomogram for gastric cancer using the national cancer registry.Oncotarget · 2016Article
- Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer.The Prostate · 2016Article
- Biomarkers for prostate cancer: present challenges and future opportunities.Future science OA · 2016Review
- Improving prediction of prostate cancer recurrence using chemical imaging.Scientific reports · 2015Article
- Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis.The American journal of pathology · 2014Article
- Performance of the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) tumor biomarker for identifying recurrent disease in African American patients.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014Article
- An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy.The British journal of radiology · 2014Review
- Chromoplexy: a new paradigm in genome remodeling and evolution.Asian journal of andrology · 2013Article
- The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing.Asian journal of andrology · 2013Review
- DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.Asian journal of andrologyReview
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
purposeThe three main treatment options for primary prostate cancer are surgery, radiation, and active surveillance. Surgical and radiation intervention for prostate cancer can be associated with significant morbidity. Therefore, accurate stratification predictive of outcome for prostate cancer patients is essential for appropriate treatment decisions. Nomograms that use clinical and pathologic variables are often used for risk prediction. Favorable outcomes exist even among men classified by nomograms as being at high risk of recurrence. EXPERIMENTAL
designPreviously, we identified a set of DNA-based biomarkers termed Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) and have shown that they can predict risk of recurrence with 80% accuracy. Here, we examined the risk prediction ability of GEMCaP in a high-risk cohort and compared it to a Kattan nomogram.
resultsWe determined that the GEMCaP genotype alone is comparable with the nomogram, and that for a subset of cases with negative lymph nodes improves upon it.
conclusionThus, GEMCaP shows promise for predicting unfavorable outcomes for negative lymph node high-risk cases, where the nomogram falls short, and suggests that addition of GEMCaP to nomograms may be warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.